[AHA 2013] Impact of Rosuvastatin on Development of New-onset Diabetes Mellitus in Asian Population: Three-year Clinical follow up Results

Abstract 13425: Impact of Rosuvastatin on Development of New-onset Diabetes Mellitus in Asian Population: Three-year Clinical follow up Results

Yoonjee Park; Seung-Woon Rha; Byoung Geol Choi; Se Yeon Choi; Raghavender Goud Akkala; Sun ki Lee; Ji Bak Kim; Sung Il Im; Jin Oh Na; Cheol Ung Choi; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Chang Gyu Park; Hong Seog Seo; Dong Joo Oh

Cardiovascular Cntr, Korea Univ Guro Hosp, Seoul, Korea, Republic of

Background: Although statin therapy is beneficial for vascular diseases, the relationship between specific statin therapy and the incidence of new-onset diabetes mellitus (DM) remains uncertain. We evaluated the impact of Rosuvastatin therapy on the development of new-onset DM from 3-year clinical follow up results in Asian population.

Methods: From January 2004 to September 2009, a total of 3,260 consecutive patients who did not have DM were enrolled. New-onset DM was defined as having a fasting blood glucose 126mg/dL or HbA1c 6.5%. Baseline characteristics between the Rosuvastatin and the control group were propensity score matched (PSM, C-statics=0.870). Three-year cumulative incidence of new-onset DM was compared between the two groups.

Results: At baseline, patients in the rosuvastatin group had a higher prevalence of elderly, male gender, dyslipidemia, coronary artery disease, cerebrovascular accident, smoking and alcoholic history, and higher levels of HbA1c, triglyceride and lower levels of HDL-C. They also had higher use of anti-hypertensive drugs; specifically beta blockers and ACEI. Five-year clinical follow up data showed a higher incidence of new-onset DM in the Rosuvastatin group (5% vs. 2%, p=0.002). Following PSM (C-statics=0.870), the 2 groups were well balanced, except for higher levels of fibrinogen, hsCRP, and ALP in the Rosuvastatin group. After further adjust, there was no difference in the incidence of new-onset DM between the 2 groups up to 3 years (Figure).

Conclusions: In our study, the relationship between the use of Rosuvastatin and the incidence of new-onset DM remains unclear. Long-term follow up with a larger study population will be necessary for further information.

Author Disclosures: Y. Park: None. S. Rha: None. B. Choi: None. S. Choi:None. R. Akkala: None. S. Lee: None. J. Kim: None. S. Im: None. J. Na: None.C. Choi: None. H. Lim: None. J. Kim: None. E. Kim: None. C. Park: None. H. Seo: None. D. Oh: None.

Key Words: Type 2 Diabetes